Ms Elizabeth de Somer  Chief Executive Officer | Medicines Australia

Ms Elizabeth de Somer
Chief Executive Officer,
Medicines Australia

PharmAus19: Medicines Matter: To the patient, the community and economy.

The third annual PharmAus Symposium provides attendees with a fantastic opportunity to hear from industry experts, key stakeholders and policy makers who will be discussing the innovative pharmaceuticals environment and explore the implications and opportunities of this rapidly evolving sector.

This year, PharmAus will be once again moderated by the very entertaining Adam Spencer and featuring a Keynote address from Professor Frank Lichtenberg - the Courtney C. Brown Professor of Business at the Columbia University Graduate School of Business.

A preliminary session guide outlining our themes is available here. We look forward to bringing you more details on our speakers in the coming weeks.

The evening will see Medicines Australia host an Innovative Medicines Showcase, where Medicines Australia member companies and other key partners will come together in the Mural Hall for exciting, interactive and educational displays providing parliamentarians with an opportunity to learn more about our sector. Each of these displays will highlight the role the industry plays in Australia, with particular reference to the patient, the community and the economy. The following morning Managing Directors of member companies and healthcare organisations will come together to discuss the challenges patients face when it comes to access to innovative medicines.

Acknowledgement of Country

Medicines Australia would like to acknowledge Ngunnawal and Ngambri peoples who are the traditional custodians of the Canberra area and pay respect to the elders, past and present, of all Australia’s Indigenous peoples.

PharmAus18 Overview

PharmAus18 saw 250 attendees from the innovative medicines industry, government, healthcare organisations and other industry stakeholders learn from industry experts and thought leaders on important issues relating to the access environment and the ongoing viability of the pharmaceutical sector.

810_1253-.jpg